Antengene Corporation

Chinese pharma companies are now taking some of their principal products to the smaller global markets of Southeast Asia, which a number are targeting in an expansion push. Hong Kong- and Shanghai-lis

Venture capital investment in biopharmaceutical companies slowed significantly from the first to the second quarter of 2022 but it remains to be seen if the third quarter will have a similar decline a

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cidara Hopes For Early 2023 Approval Of

Regulatory clearances for two CAR-T therapies and one innovative antibody-drug conjugate during 2021 highlighted the acceleration of new drug approvals in China. Throughout the year, the country’s dru